Announcements Trials
Browse Landscape

Status

No longer available 3

Sponsor Class

INDUSTRY 3

Study Type

Expanded_access 3

Sponsor

Cancer Type

CNS 2Other hematologic neoplasm 1

Conditions

Glioma 2Recurrence 1Leukemia 1

Interventions

TIC10 compound 2revumenib 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
No longer available × Expanded_access × Has announcements × Clear all
NCT05918913 2025-09-05

Expanded Access Program for Revumenib

Syndax Pharmaceuticals

No longer available
1 FDA
Other hematologic neoplasm

Leukemia, Recurrence

NCT05392374 2022-05-26

Expanded Access Use of ONC201 in a Patient With Diffuse Intrinsic Pontine Gliomas

Jazz Pharmaceuticals

No longer available
1 FDA
CNS

Glioma

NCT03134131 2022-03-14

Expanded Access to ONC201 for Patients With H3 K27M-mutant and/or Midline High Grade Gliomas

Jazz Pharmaceuticals

No longer available
1 FDA
CNS

Glioma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡